14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EW vs DXCM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DXCM Overall Winner
6-Pillar Tally: EW 3 – 3 DXCM
Matrix Metrics: EW 4 – 6 DXCM
As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin).
Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment49.2% of Rev ($3.28B)
90D Engineering Disclosures0 Published
DXCM Moat ProfileHigh-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $30.4B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment39.4% of Rev ($2.01B)
90D Engineering Disclosures0 Published
Investor FAQ EW vs DXCM Key Questions & Quantitative Answers
As of Nov 16, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas DXCM carries 53.8/100 (HOLD) at $81.58 (26.6x Forward P/E, 24.0% operating margin). Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile DXCM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with DXCM at +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while DXCM shifted +352.4%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 39.4% of Rev ($2.01B) (0 disclosures) for DXCM.
DXCM screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas DXCM trades at 26.6x Forward P/E, 32.0x Trailing P/E, 1.27x PEG, and 6.0x EV/Revenue (33.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus DXCM (37.7% ROE) capital efficiency.
In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, DXCM carries 36.9% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.64x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.